Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination of tobevibart and elebsiran in ...
BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for ...
EMERYVILLE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (FDMT) (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results